Compare ELTX & PARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | PARK |
|---|---|---|
| Founded | 2011 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.2M | 94.5M |
| IPO Year | 2014 | 2025 |
| Metric | ELTX | PARK |
|---|---|---|
| Price | $3.04 | $21.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | ★ 269.9K | 18.3K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.29 | N/A |
| EPS | N/A | ★ 0.16 |
| Revenue | ★ $2,301,000.00 | N/A |
| Revenue This Year | N/A | $7.06 |
| Revenue Next Year | N/A | $6.17 |
| P/E Ratio | ★ N/A | $132.50 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.66 | $12.29 |
| 52 Week High | $16.00 | $26.79 |
| Indicator | ELTX | PARK |
|---|---|---|
| Relative Strength Index (RSI) | 41.08 | 55.94 |
| Support Level | $2.72 | $16.63 |
| Resistance Level | $3.28 | $21.86 |
| Average True Range (ATR) | 0.17 | 1.89 |
| MACD | 0.12 | 0.12 |
| Stochastic Oscillator | 51.24 | 38.58 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.